Mechanism of Action
Broader Receptor Profile Than Somatostatin
Unlike somatostatin, cortistatin activates not only all five somatostatin receptors but also the ghrelin/" class="wiki-internal-link">ghrelin receptor GHSR-1a and MrgX2 on mast cells and neurons. GHSR-1a activation promotes slow-wave sleep and GH release. MrgX2 activation modulates neurogenic inflammation. This broader receptor profile explains the divergent biological activities between cortistatin and somatostatin despite their structural similarity.
Immunomodulatory Actions
Cortistatin potently suppresses macrophage and T-cell activation, reducing production of TNF-alpha, IL-6, IL-12, and nitric oxide. In animal models of inflammatory disease, peripheral cortistatin achieves anti-inflammatory effects comparable to glucocorticoids without metabolic side effects. The anti-inflammatory actions are mediated primarily through SSTR2 and SSTR3 on immune cells.
Research Summary
Inflammatory Disease Models
AnimalCortistatin demonstrated powerful therapeutic effects in animal models of rheumatoid arthritis, Crohn's disease, and septic shock. In collagen-induced arthritis, cortistatin injection significantly reduced joint inflammation and bone erosion, outperforming somatostatin in efficacy.
Sleep and Neuroendocrine
HumanHuman infusion studies confirmed that cortistatin increases slow-wave sleep duration and suppresses REM sleep, consistent with animal findings. The peptide also stimulates GH release, suggesting dual applications in sleep quality and recovery.
Neuroprotection
AnimalCortistatin protected against hippocampal neurodegeneration in excitotoxic and ischemic models. The peptide reduced neuronal apoptosis and inflammatory microglial activation in multiple CNS injury models.
Calculate your Cortistatin-14 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anti-inflammatory research | 250-500 mcg | Daily or alternate days | Subcutaneous or IP |
| Sleep research | 25-100 mcg/kg | Single evening dose | Subcutaneous or IV |
Most protocols derived from animal studies. No established human therapeutic dosing.
Interactions
Safety Profile
Animal studies report no significant toxicity at effective doses. Human sleep infusion studies were well tolerated. Potential concerns include hormonal effects via SSTR and GHSR signaling, particularly GH stimulation with long-term use. Cortistatin is an endogenous peptide, suggesting intrinsic compatibility with normal physiology.
References
- [1]de Lecea L, et al. A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature. 1996;381:242-245.
- [2]Gonzalez-Rey E, et al. Cortistatin, an antiinflammatory peptide with therapeutic promise. Trends Mol Med. 2007.
- [3]Dalm VA, et al. Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system. J Clin Endocrinol Metab. 2003.